证券日报网讯奇正藏药（002287）8月4日在互动平台回答投资者提问时表示，截至2025年7月31日，公 司股东总人数为26327户。 ...

Group 1: New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - ST Kelly (300326) has a tender offer period from July 17, 2025, to August 15, 2025[1] - ST Zitian (300280) has a tender offer period ending on July 21, 2025[1] Group 2: Market Alerts - Xizang Tourism (600749) reported severe abnormal fluctuations on July 31, 2025[1] - Tianlu Convertible Bonds (110060) announced significant market activity on July 30, 2025[1] - ST Suwu (600200) experienced unusual trading patterns on July 30, 2025[1] Group 3: Additional Announcements - Happiness Blue Ocean (300528) issued a notice on July 30, 2025, regarding market conditions[1] - Common Pharmaceutical (300966) provided updates on August 1, 2025, related to stock performance[1] - Dongjie Intelligent (300486) released a statement on August 1, 2025, concerning market volatility[1]

格隆汇8月4日丨奇正藏药(002287.SZ)在互动平台表示，公司暂无药品直接用于基孔肯雅热病毒的治 疗。 ...

陇神戎发涨超10%，奇正藏药此前涨停，粤万年青、新天药业、盘龙药业、佛慈制药等跟涨。 (本文来自第一财经) ...

每经AI快讯，8月4日，中药股探底回升，陇神戎发一度涨超10%，奇正藏药此前涨停，粤万年青、新天 药业、盘龙药业、佛慈制药等跟涨。 （文章来源：每日经济新闻） ...

A股中药板块高开，奇正藏药4连板，新天药业、太龙药业、贵州百灵、维康药业、康缘药业跟涨。 ...

中药板块高开，奇正藏药4连板，新天药业、太龙药业、贵州百灵、维康药业、康缘药业跟涨。 ...

Group 1 - The company issued convertible bonds totaling 800 million RMB with a face value of 100 RMB each, approved by the China Securities Regulatory Commission on September 22, 2020 [1][2] - The bonds were listed on the Shenzhen Stock Exchange on October 27, 2020, under the name "奇正转债" and code "128133" [2] - The conversion period for the bonds starts from March 29, 2021, and ends on September 21, 2026 [3] Group 2 - The conversion price of the bonds has been adjusted multiple times, starting from 30.12 RMB/share to 29.78 RMB/share on July 8, 2021, and further adjustments down to 19.01 RMB/share by July 10, 2025 [4][5][6][7] - The company experienced a significant trading fluctuation, with the bond price deviating by over 30% during three consecutive trading days in late July 2025 [8] Group 3 - The company confirmed that there were no undisclosed significant matters affecting the bond's trading price and that its operational status remains normal [8][9] - As of August 1, 2025, the closing price of the bonds was 197.00 RMB, representing a premium of 97.00% over the face value, with a conversion value of 182.4829 RMB and a conversion premium rate of 7.96% [8]

Group 1 - The company issued convertible bonds totaling 800 million RMB with a face value of 100 RMB per bond, approved by the China Securities Regulatory Commission [1] - The bond interest rates are structured to increase from 0.40% in the first year to 2.50% in the sixth year [1] - The convertible bonds are listed on the Shenzhen Stock Exchange under the name "Qizheng Convertible Bonds" with the code "128133" [1] Group 2 - The conversion period for the bonds started on March 29, 2021, and will end on September 21, 2026 [2] - The conversion price has been adjusted multiple times, with the latest adjustment on January 24, 2025, reducing the price from 19.61 RMB to 19.39 RMB per share [5] - The bond's conversion price was also adjusted to 20.09 RMB on February 20, 2024, reflecting the company's strategic decisions based on market conditions [4] Group 3 - The company experienced a significant trading fluctuation, with the bond's closing price deviating by over 30% for three consecutive trading days [6] - The bond's conversion value is reported at 182.4829 RMB per bond, with a conversion premium rate of 7.96% [6][7] - The company confirmed that there are no undisclosed significant matters affecting the bond's trading price [6]

Market Performance - The two markets opened lower on Friday, with the Shanghai Composite Index closing at 3559.95 points, down 0.37%, and the Shenzhen Component down 0.17% [1] - The total trading volume was 15,984 billion, a significant decrease of 3,377 billion (-17.44%) compared to Thursday [1] - Over 80% of industry sectors saw gains, with warehousing logistics, construction decoration, software, paper printing, and ecological environment sectors leading the rise [1] Industry Highlights - The Chinese medicine sector experienced a significant surge, with Weikang Pharmaceutical hitting the 20% daily limit, alongside other companies like Tianmu Pharmaceutical and Guizhou Bailin also reaching the limit [1] - The photovoltaic sector also performed well, with Jiejia Weichuang and Shuangliang Energy both hitting the daily limit [1] Technical Analysis - The three major indices showed a volume contraction and closed with long upper shadows, indicating a potential reversal after five consecutive weeks of gains [2] - The Shanghai Composite, Shenzhen Component, and ChiNext Index fell by 0.94%, 1.58%, and 0.74% respectively for the week, with total trading volume at 8.93 trillion, down 1.76% from the previous week [2] Investment Strategy - Companies are advised to reduce positions in high-flying stocks that have seen significant gains, while looking to invest in undervalued small and mid-cap growth stocks that have shown strong performance in Q1 and exceeded expectations in H1 [2] - There is a recommendation to allocate some resources towards brokerage stocks in anticipation of the upcoming half-year and third-quarter earnings reports [2]